GR3020861T3 - Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands - Google Patents

Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands

Info

Publication number
GR3020861T3
GR3020861T3 GR960402218T GR960402218T GR3020861T3 GR 3020861 T3 GR3020861 T3 GR 3020861T3 GR 960402218 T GR960402218 T GR 960402218T GR 960402218 T GR960402218 T GR 960402218T GR 3020861 T3 GR3020861 T3 GR 3020861T3
Authority
GR
Greece
Prior art keywords
bone
complexes
image enhancement
mri image
related tissue
Prior art date
Application number
GR960402218T
Other languages
English (en)
Inventor
Harry S Winchell
Joseph Y Klein
Elliot D Simhon
Rosa L Cyjon
Ofer Klein
Haim Zaklad
Original Assignee
Concat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concat Ltd filed Critical Concat Ltd
Publication of GR3020861T3 publication Critical patent/GR3020861T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01R—MEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00—Arrangements or instruments for measuring magnetic variables
    • G01R33/20—Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44—Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/48—NMR imaging systems
    • G01R33/54—Signal processing systems, e.g. using pulse sequences ; Generation or control of pulse sequences; Operator console
    • G01R33/56—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution
    • G01R33/5601—Image enhancement or correction, e.g. subtraction or averaging techniques, e.g. improvement of signal-to-noise ratio and resolution involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Signal Processing (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GR960402218T 1989-11-27 1996-08-22 Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands GR3020861T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44114489A 1989-11-27 1989-11-27
PCT/US1990/005967 WO1991007911A1 (en) 1989-11-27 1990-10-17 Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands

Publications (1)

Publication Number Publication Date
GR3020861T3 true GR3020861T3 (en) 1996-11-30

Family

ID=23751720

Family Applications (1)

Application Number Title Priority Date Filing Date
GR960402218T GR3020861T3 (en) 1989-11-27 1996-08-22 Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands

Country Status (10)

Country Link
EP (1) EP0513000B1 (el)
JP (1) JP2593963B2 (el)
AT (1) ATE140869T1 (el)
AU (1) AU649001B2 (el)
CA (1) CA2069638C (el)
DE (1) DE69028001T2 (el)
DK (1) DK0513000T3 (el)
ES (1) ES2091251T3 (el)
GR (1) GR3020861T3 (el)
WO (1) WO1991007911A1 (el)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885549A (en) * 1991-02-01 1999-03-23 Imarx Pharmaceutical Corp. Phosphorylated materials as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
US5143716A (en) * 1991-02-01 1992-09-01 Unger Evan C Phosphorylated sugar alcohols, Mono- and Di-Saccharides as contrast agents for use in magnetic resonance imaging of the gastrointestinal region
MX9207168A (es) * 1991-12-10 1993-12-01 Dow Chemical Co Composiciones orales para inhibir la formacion de placa y de calculos.
US5555884A (en) * 1992-12-16 1996-09-17 Kabushiki Kaisha Egawa Measuring method by using resonance of a resonance medium
US5714604A (en) * 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
US5409689A (en) * 1993-08-13 1995-04-25 Concat, Ltd. MRI image enhancement using complexes of paramagnetic cations and amine ligands containing a mixture of phosphonate and non-phosphonate pendant arms
US5834456A (en) * 1996-02-23 1998-11-10 The Dow Chemical Company Polyazamacrocyclofluoromonoalkylphosphonic acids, and their complexes, for use as contrast agents
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
US6565828B2 (en) * 2000-04-07 2003-05-20 Bristol-Myers Squibb Company Macrocyclic chelants for metallopharmaceuticals
EP1637524A1 (en) * 2004-09-20 2006-03-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. 10-substituted 1-, 4, 7,-tris (carboxymethyl)-1,4,7,10-tetraazacyclo-dodecane derivative for use as contrast agents
JP5690733B2 (ja) * 2009-08-20 2015-03-25 富士フイルムＲｉファーマ株式会社 ビスホスホン酸誘導体及びその放射性金属核種標識体

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515766A (en) * 1980-06-23 1985-05-07 The Massachusetts General Hospital Labeled phosphonic acid compositions for investigations of in vivo deposits of calcium
DE3129906C3 (de) * 1981-07-24 1996-12-19 Schering Ag Paramagnetische Komplexsalze, deren Herstellung und Mittel zur Verwendung bei der NMR-Diagnostik
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
DE3237573A1 (de) * 1982-10-09 1984-04-12 Hoechst Ag, 6230 Frankfurt Technetium-99m-tri- und tetraphosphonate zur szintigraphischen dastellung res-haltiger organe und der lymphgefaesse und verfahren zu deren herstellung
FR2550449B1 (fr) * 1983-08-12 1986-01-31 Commissariat Energie Atomique Agents de relaxation specifiques d'organes ou de pathologies, utilisables pour modifier les contrastes en imagerie medicale par resonance magnetique nucleaire
US4749560A (en) * 1984-08-13 1988-06-07 Research Corporation Metal organo phosphorous compounds for NMR analysis
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
GB8518300D0 (en) * 1985-07-19 1985-08-29 Amersham Int Plc Contrast agent
AU608759B2 (en) * 1986-08-04 1991-04-18 Amersham Health Salutar Inc NMR imaging with paramagnetic polyvalents metal salts of poly-(acid-alkylene-amido)-alkanes
GB8701054D0 (en) * 1987-01-16 1987-02-18 Amersham Int Plc Contrast agent for nmr scanning
GB8903023D0 (en) * 1989-02-10 1989-03-30 Parker David Chemical compounds
GB8914543D0 (en) * 1989-06-23 1989-08-09 Parker David Chemical compounds
PT98000B (pt) * 1990-06-18 1998-11-30 Dow Chemical Co Metodo de utilizacao de complexos de acido aminofosfonico como agentes produtores de imagens

Also Published As

Publication number Publication date
ES2091251T3 (es) 1996-11-01
CA2069638C (en) 1999-02-09
CA2069638A1 (en) 1991-05-28
EP0513000A4 (en) 1992-09-01
WO1991007911A1 (en) 1991-06-13
AU649001B2 (en) 1994-05-12
DE69028001D1 (de) 1996-09-05
DE69028001T2 (de) 1996-12-19
ATE140869T1 (de) 1996-08-15
DK0513000T3 (da) 1996-12-30
JPH05504127A (ja) 1993-07-01
AU6732290A (en) 1991-06-26
EP0513000A1 (en) 1992-11-19
EP0513000B1 (en) 1996-07-31
JP2593963B2 (ja) 1997-03-26

Similar Documents

Publication Publication Date Title
ATE262329T1 (de) Formulierungen und verfahren zur verminderung der toxizität von anti-neoplastischen mitteln
FI922151A0 (fi) Metall-peptidkompositioner och metoder foer stimulering av haortillvaext.
FI911319A0 (fi) Polypeptidderivat.
ATE170077T1 (de) Verfahren zur behandlung von krebs durch kombinationstherapie mit 2'- halomethylidenderivaten und einem s- oder m-phase spezifischen antineoplastischen wirkstoff
GR3020861T3 (en) Mri image enhancement of bone and related tissue using complexes of paramagnetic cations and polyphosphonate ligands
ATE212846T1 (de) Bisphosphonat und anti-resorption agentien, enthaltende zusammensetzungen zur hemmung der knochenschwund
ATE235921T1 (de) Phosphonate- und nicht-phosphonate einheiten enthaltende polyamino-paramagnetische-chelate fuer anwendung in mri
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
ATE131073T1 (de) Konjugate zur knochenbilddarstellung und therapie von knochenkrebs.
FI895141A0 (fi) Kelatmedel med orto-ligerande funktionalitet och deras komplexer.
GEP20053423B (en) Method of Inhibiting Amyloid Protein Aggregation and Method for Imaging of Amyloid Deposits
FI101597B1 (fi) Menetelmä kylmäkuivatun koostumuksen valmistamiseksi käytettäväksi potilaan valodynaamisessa hoidossa tai diagnosoinnissa
IL101675A0 (en) Method and pharmaceutical compositions for detecting and localizing tissues having neurokinine 1 receptors
ZA81927B (en) Phenylpiperazine derivatives of 1,3,4-oxadiazolyphenols their preparation and therapeutic agents containing these compounds
FI902901A0 (fi) Dibenzol/1,5/dioxocin-5-one-derivat, deras anvaendning i laekemedel och foerfarande foer deras framstaellning.
DK601888A (da) Anvendelse af 2-pyrimidinyl-1-piperazinderivater
ATE147978T1 (de) Verwendung von (e) - 2 - (p -fluorophenethyl)- 3 - fluoroallylamine zur behandlung der alzheimerschen krankheit
ES2032209T3 (es) Derivados de proteinas que contienen hierro en forma altamente biodisponible, su preparacion y composiciones farmaceuticas que los contienen.
EP0948361A4 (en) MAGNETIC RESONANCE BLOOD POOL IMAGING AGENTS
ATE96035T1 (de) Verwendung eines polypeptides mit gammainterferon-aktivitaet zur herstellung von pharmazeutischen zusammensetzungen zur behandlung von primitivem pleura-krebs.
RU92016532A (ru) Бензохиназолиновые соединения, способ их получения, фармацевтическая композиция и способ лечения
EP0480458A3 (en) Process for the preparation of pharmaceutical compositions containing viminol useful in the treatment of drug dependences
IT1242026B (it) Composizione farmaceutica contenente un complesso ferro-schizokinene per il trattamento dell'anemia ferropenica.
ATE74770T1 (de) Tc-99m-w-alkylphosphinico-1-hydroxyalkan-1,1diphosphonate enthaltende praeparate zur knochenszintigraphie sowie verfahren zur herstellung dieser praeparate.
FI964849A0 (fi) Pyridyylibisfosfonaatit käytettäväksi terapeuttisina aineena